← Back to Search

Radiation Therapy

Stereotactic Ablative Radiation Therapy for Kidney Cancer

Phase 2
Waitlist Available
Led By Raquibul Hannan, MD, PhD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Biopsy proven Renal neoplasm
Age ≥ 18 years
Must not have
Subject has received any treatment for the treating renal mass; such as RFA or cyroablation
Subjects received previous abdominal radiation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new, non-invasive treatment for small renal tumors. The goal is to see if it is effective.

Who is the study for?
This trial is for adults with small kidney tumors (≤5cm) that have been biopsy-proven and shown growth. Participants must be able to undergo MRI or CT scans, use effective contraception if of childbearing potential, and not be pregnant. Those who've had prior treatments for the renal mass or have metastatic disease (with exceptions) can't join.
What is being tested?
The study is testing Stereotactic Ablative Radiation Therapy (SABR), a non-invasive treatment targeting small growing renal tumors. It's a phase II trial aiming to assess how well this therapy works in eliminating cancer cells without surgery.
What are the potential side effects?
Potential side effects of SABR may include fatigue, skin reactions at the treatment site, nausea, changes in urinary habits, and abdominal pain. The exact side effects can vary based on individual patient factors.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney tumor was confirmed by a biopsy.
Select...
I am 18 years old or older.
Select...
My kidney tumor grew more than 2mm in a year.
Select...
I am a woman who could still become pregnant.
Select...
My kidney tumor is 5cm or smaller.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have undergone treatments like RFA or cryoablation for my kidney tumor.
Select...
I have had radiation therapy to my abdomen before.
Select...
I am not pregnant nor planning to become pregnant during the treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Eliminate its growth and tumor viability.
Secondary study objectives
Adverse events
Renal function
Tumor Viability
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stereotactic Ablative Radiation TherapyExperimental Treatment1 Intervention
Stereotactic Ablative Radiation Therapy (SABR)

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
1,089 Previous Clinical Trials
1,059,667 Total Patients Enrolled
Raquibul Hannan, MD, PhDPrincipal InvestigatorUTSW
5 Previous Clinical Trials
101 Total Patients Enrolled

Media Library

Stereotactic Ablative Radiation Therapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02141919 — Phase 2
Kidney Cancer Research Study Groups: Stereotactic Ablative Radiation Therapy
Kidney Cancer Clinical Trial 2023: Stereotactic Ablative Radiation Therapy Highlights & Side Effects. Trial Name: NCT02141919 — Phase 2
Stereotactic Ablative Radiation Therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02141919 — Phase 2
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top